Full-Time

Director/Senior Director

National Accounts, East

Stoke Therapeutics

Stoke Therapeutics

201-500 employees

Develops targeted gene upregulation therapies

Compensation Overview

$238k - $322k/yr

+ Bonus + Equity Participation

Waltham, MA, USA + 1 more

More locations: Bedford, MA, USA

Hybrid

Relocation to Waltham, MA by end of 2026; remote/field-based with ~50% travel.

Bachelor's, Master's, MBA, PharmD

Category
Medical, Clinical & Veterinary (1)

Get referred to Stoke Therapeutics

See people who can refer or advise you

Requirements
  • Bachelor’s degree required; advanced degree (MBA, MPH, PharmD) preferred.
  • 15+ years in pharma/biotech; minimum 10 years in payer account management with lead responsibility for one of the three large PBM and National accounts.
  • Proven track record of achieving positive coverage outcomes for orphan designation or rare disease products on the medical benefit.
  • Pre-launch payer strategy experience—not just maintenance of established access.
  • Hands-on experience navigating a miscellaneous J code (J3490/J3590) environment, including transition to a permanent product-specific code.
  • Strong command of managed care economics, formulary management, utilization management, and coverage policy development processes at national payers.
  • Rare pediatric or neurological disease product launch experience; CNS or epilepsy payer experience a significant differentiator.
  • Familiarity with disease-modifying therapy and gene testing reimbursement pathways as established according to payer policy.
  • Experience at a company building its commercial infrastructure for the first time—startup or early commercial-stage biotech.
  • Exceptional ability to influence across functions without direct authority.
  • Passion for patient access and rare-disease impact.
Responsibilities
  • Develop and execute pre-launch and launch-phase access strategies, establishing Stoke’s presence with key accounts.
  • Serve as strategic leader for key accounts in the region
  • Develop account-specific action plans that shorten the timeline from FDA approval to an active, positive coverage determination.
  • Build payer relationships and establish Stoke’s credibility with medical benefit policy decision-makers before NDA submission, ensuring seamless coverage between approval and patient access.
  • Develop multi-year access plans that anticipate commercial cycles and competitive coverage shifts, balancing account-level execution with a national access strategy.
  • Educate payers on clinical evidence, FDA labeling, treatment guidelines, and health-economic data to support coverage decisions and eliminate utilization management barriers (step edits, PA criteria, NDC blocks).
  • Monitor medical policy language at each account and partner with Medical Affairs, HEOR, and Advocacy to respond to and proactively shape policy criteria.
  • Proactively engage payer Medical Directors to obtain informal guidance letters or billing instructions that bridge the gap between launch and permanent J code assignment.
  • Engage and influence policy decision-makers for a medical benefit product to achieve desired coverage policy outcomes.
  • Serve as the company’s subject-matter expert on buy-and-bill reimbursement dynamics for products carrying a miscellaneous J code (J3490/J3590) pending assignment of a permanent, product-specific J code.
  • Educate payer medical policy teams on correct claims submission procedures, billing unit conventions, and NDC-to-J code crosswalk requirements to minimize claim denials during the unclassified code period.
  • Drive alignment across Stoke’s commercial team and field medical team without direct reporting relationships, building internal coalitions across Medical, HEOR, Reimbursement, Government Affairs, Legal, Trade & Distribution, and Patient Services to ensure integrated execution.
  • Ensure effective communication and coordination between the field reimbursement team and patient services to support a high approval success rate and timely patient access.
  • Engage authentically with the Dravet syndrome patient and caregiver community and incorporate community insights into payer engagement in a compelling and compliant manner.
  • Conduct all payer engagements in full compliance with company SOPs, OIG guidelines, PhRMA Code, and applicable federal and state regulations.
  • Navigate the unique complexity of a first-in-class disease-modifying ASO therapy with no established coverage precedent, finding creative and compliant paths to access.

Stoke Therapeutics develops therapies for severe genetic diseases caused by loss of function in a single gene, aiming to restore missing proteins by upregulating protein expression. Its main product approach relies on the TANGO (Targeted Augmentation of Nuclear Gene Output) platform, which delivers precise, durable, and controllable upregulation of gene expression across a range of tissues to re-create the missing protein. Compared with many biotech firms, Stoke centers on upregulating endogenous gene output rather than replacing genes or adding new ones, and focuses on disease-modifying treatments for rare disorders with unmet medical needs. Revenue comes from partnerships, licensing agreements, and, ultimately, commercialization of its therapies. The company’s goal is to provide targeted, durable treatments that address the underlying genetic deficiency and improve outcomes for patients with limited options.

Company Size

201-500

Company Stage

IPO

Headquarters

Bedford, Texas

Founded

2014

Get referred to Stoke Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • EMPEROR enrollment hit 162 patients by August 3, 2026, above target.
  • The FDA accepted a rolling NDA plan for first-half 2027.
  • NEJM March 4, 2026 publication strengthened zorevunersen’s seizure and cognition data.

What critics are saying

  • EMPEROR readout lands mid-2027; one bad result kills the 2028 launch story.
  • Stoke still burned $61.6 million in Q2 2026, despite $420 million cash.
  • STK-002 remains early-stage; zorevunersen failure leaves Stoke with one asset.

What makes Stoke Therapeutics unique

  • Zorevunersen targets SCN1A haploinsufficiency in Dravet syndrome, not symptoms alone.
  • Stoke’s TANGO platform upregulates native protein expression with disease-modifying intent.
  • Biogen partnership preserves U.S. rights while financing ex-U.S. commercialization.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

3%

2 year growth

1%
MarketBeat
Aug 5th, 2026
Stoke Therapeutics (NASDAQ:STOK) insider sells $208,391.04 in stock.

Stoke Therapeutics (NASDAQ:STOK) insider sells $208,391.04 in stock. August 5, 2026 Key points. * Insider sale: Barry Ticho sold 7,176 Stoke Therapeutics shares for approximately $208,391 under a Rule 10b5-1 plan, reducing his holdings by 26% to 20,422 shares. * Mixed quarterly results: Stoke reported $9.32 million in revenue, well above the $4.89 million consensus estimate, but its $0.93 quarterly loss per share was wider than expected. The company remains unprofitable, with a negative net margin of 753.6%. * Pipeline and analyst outlook: Management plans to submit a rolling NDA for zorevunersen in the first quarter of 2027 and potentially launch in the U.S. by early 2028. Analysts remain generally bullish, with a consensus "Moderate Buy" rating and an average price target of $43 versus the reported share price of $31.93. * Interested in Stoke Therapeutics? Here are five stocks we like better. Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 7,176 shares of the company's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $29.04, for a total transaction of $208,391.04. Following the completion of the sale, the insider owned 20,422 shares in the company, valued at approximately $593,054.88. This trade represents a 26.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Barry Ticho also recently made the following trade(s): * On Monday, June 1st, Barry Ticho sold 1,795 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.58, for a total value of $54,891.10. Stoke Therapeutics trading up 0.8%. Stoke Therapeutics stock traded up $0.26 during midday trading on Wednesday, hitting $31.93. The stock had a trading volume of 634,783 shares, compared to its average volume of 753,262. The stock has a market cap of $1.99 billion, a P/E ratio of -11.36 and a beta of 1.20. Stoke Therapeutics, Inc. has a 12 month low of $12.75 and a 12 month high of $40.22. The business has a fifty day moving average price of $30.40 and a 200 day moving average price of $32.01. Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.13). The firm had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.09% and a negative net margin of 753.60%. On average, equities analysts anticipate that Stoke Therapeutics, Inc. will post -3.22 EPS for the current fiscal year. Institutional investors weigh in on Stoke Therapeutics. Hedge funds and other institutional investors have recently modified their holdings of the stock. Tema ETFs LLC grew its position in Stoke Therapeutics by 16.1% in the 2nd quarter. Tema ETFs LLC now owns 9,917 shares of the company's stock valued at $324,000 after buying an additional 1,377 shares in the last quarter. Generali Investments Management Co LLC increased its stake in shares of Stoke Therapeutics by 379.6% during the second quarter. Generali Investments Management Co LLC now owns 33,149 shares of the company's stock valued at $1,085,000 after acquiring an additional 26,237 shares during the period. Assenagon Asset Management S.A. raised its holdings in Stoke Therapeutics by 24.4% during the second quarter. Assenagon Asset Management S.A. now owns 1,128,388 shares of the company's stock worth $36,921,000 after purchasing an additional 221,373 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Stoke Therapeutics by 22.6% during the 2nd quarter. Versant Capital Management Inc now owns 1,951 shares of the company's stock valued at $64,000 after purchasing an additional 359 shares during the period. Finally, Western Wealth Management LLC bought a new stake in shares of Stoke Therapeutics in the 1st quarter worth $55,000. Key Stoke Therapeutics news. Here are the key news stories impacting Stoke Therapeutics this week: * Positive Sentiment: Stoke outlined plans to submit a rolling New Drug Application (NDA) for zorevunersen in the first quarter of 2027, with a potential U.S. launch by early 2028. Management said its approximately $420 million in cash supports development and launch preparations, reducing near-term financing concerns. Stoke outlines rolling NDA in Q1 2027 * Positive Sentiment: Second-quarter revenue of roughly $9.3 million substantially exceeded the $4.89 million analyst consensus, despite the company remaining unprofitable. The earnings call and business update highlighted continued progress in Stoke's Dravet syndrome program. Second-quarter 2026 financial results * Positive Sentiment: Analyst support remains strong. Guggenheim reaffirmed a Buy rating with a $60 price target, while Wedbush maintained Outperform and raised its target to $40. Chardan also reiterated Buy with a $35 target. Analyst ratings * Neutral Sentiment: Stoke is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference, which could provide additional visibility into its pipeline and regulatory plans but does not represent a new operating update by itself. Canaccord Genuity conference presentation * Negative Sentiment: Stoke reported a second-quarter loss of $0.93 per share, wider than the approximately $0.80-$0.82 consensus loss and worse than the $0.40 loss a year earlier. HC Wainwright also reduced its FY2029 EPS estimate to $1.55 from $1.63 and FY2030 estimate to $3.56 from $3.74. Second-quarter loss and revenue results Analysts set new price targets. A number of research firms have commented on STOK. Weiss Ratings downgraded shares of Stoke Therapeutics from a "hold (c)" rating to a "sell (d)" rating in a report on Monday, May 11th. Canaccord Genuity Group reduced their price target on shares of Stoke Therapeutics from $60.00 to $58.00 and set a "buy" rating on the stock in a research report on Tuesday. BTIG Research reiterated a "buy" rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research note on Monday, May 11th. Guggenheim reissued a "buy" rating and issued a $60.00 target price on shares of Stoke Therapeutics in a report on Tuesday. Finally, Wedbush upped their target price on Stoke Therapeutics from $38.00 to $40.00 and gave the company an "outperform" rating in a report on Tuesday. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $43.00. About Stoke Therapeutics. Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO(TM) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins. The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Stoke Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list. While Stoke Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

Dravet Syndrome Foundation
Jul 19th, 2026
2026 DSF Catalyst for Change Award: Stoke Therapeutics.

2026 DSF Catalyst for Change Award: Stoke Therapeutics. The 2026 Catalyst for Change Award was proudly presented to Stoke Therapeutics in recognition of its outstanding contributions to the field of Dravet syndrome. Through a steadfast commitment to developing innovative therapies, Stoke Therapeutics has demonstrated strong and purposeful leadership, translating scientific discovery into real hope for families. Equally important, the company has consistently placed the patient voice at the center of its efforts. By actively engaging individuals and families affected by Dravet syndrome, Stoke ensures that lived experience informs clinical research, guides development strategies, and shapes decision-making at every stage. Stoke Therapeutics' dedication to advancing cutting-edge science while fostering authentic partnership with the community truly embodies the spirit of the Catalyst for Change Award.

Associated Press
Jul 13th, 2026
Stoke Therapeutics names Thomas McCauley chief scientific officer to expand RNA medicine pipeline

Stoke Therapeutics has appointed Thomas McCauley as chief scientific officer. The biotechnology company, which is developing RNA medicines to restore protein expression, announced that McCauley will lead its scientific strategy and platform expansion. McCauley brings over 25 years of experience in research and development, including six years at Shire where he contributed to late-stage development and global approvals of genetic medicines for rare diseases. He most recently served as president and chief executive officer of Neptune Bio. In his new role, McCauley will work to advance Stoke's pipeline beyond its lead investigational medicine, zorevunersen, which is being developed as a potential disease-modifying treatment for Dravet syndrome. He previously held chief scientific officer positions at Omega Therapeutics, Macrolide Pharmaceuticals and Translate Bio.

The Pharma Letter
Jul 13th, 2026
Stoke Tx appoints Thomas McCauley as CSO.

Stoke Tx appoints Thomas McCauley as CSO. 13 July 2026 US RNA medicines focused biotech Stoke Therapeutics (Nasdaq: STOK) today announced that Thomas McCauley has been appointed chief scientific officer (CSO). Dr McCauley joins Stoke with more than 25 years of experience leading high-performing R&D teams and translating early scientific discoveries into clinical programs that have delivered new medicines to people living with severe diseases. He brings extensive expertise in developing novel technology platforms and modalities across multiple therapeutic areas, including six years at Shire where he played a key role in the late-stage development and global approvals of multiple genetic medicines for rare diseases. In this new role, he will be responsible for leading Stoke's scientific strategy and leveraging the company's proprietary RNA medicines platform to expand and advance its pipeline. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 10 October 2025 31 January 2023 10 January 2022 Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 13 July 2026 Company spotlight. A clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. More features in biotechnology. 13 July 2026

Business Wire
Apr 7th, 2026
Stoke Therapeutics appoints Clare Kahn to board as Dravet syndrome treatment advances to Phase 3

Stoke Therapeutics has appointed Clare Kahn, PhD, to its Board of Directors. The Bedford, Massachusetts-based biotechnology company is developing zorevunersen, an investigational RNA medicine for Dravet syndrome, a severe genetic epilepsy. Dr Kahn brings over 30 years of pharmaceutical industry experience, most recently serving as R&D Strategy Officer at X-VAX Technology. She previously held senior positions at Pfizer and GlaxoSmithKline, with expertise in regulatory strategy and rare genetic disease development. The appointment comes as Stoke advances a Phase 3 clinical study of zorevunersen, which targets the underlying cause of Dravet syndrome. The company has a strategic collaboration with Biogen for the drug's development and commercialisation, retaining exclusive US, Canada and Mexico rights whilst Biogen holds rest-of-world rights.